Physician profile
Michael Holman
NPI 1073576070
$8,190.44
in general payments reported to CMS, 2019-2025
33 companies · $764 in 2025
The $764 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $874 · 2021: $1,182 · 2022: $1,090 · 2023: $1,562 · 2024: $1,557 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,882.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,468.62 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,261.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,090.18 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,000.98 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $605.04 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $584.73 | 2019-2024 | Ofev |
| Lilly USA, LLC | $386.97 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $324.15 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $264.35 | 2020-2024 | Verquvo, Belsomra, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.69 | 2019-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $145.20 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $132.07 | 2023-2025 | Rexulti |
| Amgen INC. | $120.72 | 2019-2024 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $81.87 | 2021-2024 | |
| Allergan, INC. | $73.66 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $72.28 | 2021-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $46.61 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $44.36 | 2021-2024 | Eliquis |
| Astellas Pharma US INC | $41.21 | 2019-2023 | Veozah |
| Mylan Specialty L.P. | $34.60 | 2019-2023 | Yupelri |
| Averitas Pharma INC. | $27.87 | 2025 | Qutenza |
| Xeris Pharmaceuticals, INC. | $24.45 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.32 | 2025 | Caplyta |
| Avion Pharmaceuticals | $23.98 | 2020 | |
| Dexcom, INC. | $22.83 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.76 | 2024 | |
| Sunovion Pharmaceuticals INC. | $17.68 | 2021 | |
| Abbott Laboratories | $17.24 | 2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $17.01 | 2023 | Gemtesa |
| Medtronic, INC. | $14.58 | 2023 | Interstim |
| Inari Medical, INC. | $14.21 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Phathom Pharmaceuticals, INC. | $13.73 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $13.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Holman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.